eligibility_summary
Inclusion: MM per IMWG, previously exposed to PI, IMiD, and anti-CD38, documented progression after last regimen, ECOG 0-1 (2-3 allowed if due to stable non-MM limitations), able to follow lifestyle limits. Exclusion: allergy to study drugs, stroke/TIA/seizure <=6 mo, within 6 mo MI/unstable angina/major thromboembolism/significant ventricular arrhythmia/NYHA III-IV, major surgery <=2 wks/not recovered/planned, severe or unresolved dysgeusia/WETT severe or oral pathology.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, open-label, randomized study in relapsed/refractory multiple myeloma (triple-class–exposed) testing talquetamab ± oral prophylactic regimens (Prophylaxis A/B/C, mechanisms not disclosed) to prevent talquetamab-related dysgeusia. Interventions: Talquetamab (subcutaneous), a GPRC5D×CD3 bispecific T‑cell–redirecting monoclonal antibody (biologic) that binds CD3 on T cells and GPRC5D on target cells, activating T-cell cytotoxicity and cytokine release. Targets/cells/pathways: malignant plasma cells expressing GPRC5D, T cells via CD3-mediated activation and immune synapse formation, off-tumor GPRC5D in oral/keratinized tissues implicated in taste changes. Prophylaxis A/B/C are oral agents, specific MOAs not provided.